Treatment and outcome of 2904 CML patients from the EUTOSpopulation-based registry
2017
The European Treatment and Outcome Study (EUTOS)
population-based registry includes data of all adult patients
newly diagnosed with Philadelphia chromosome-positive and/or
BCR-ABL1+ chronic myeloid leukemia (CML) in 20 predefined
countries and regions of Europe. Registration time ranged from
12 to 60 months between January 2008 and December 2013. Median
age was 55 years and median observation time was 29 months.
Eighty percent of patients were treated first line with
imatinib, and 17% with a second-generation tyrosine kinase
inhibitor, mostly according to European LeukemiaNet
recommendations. After 12 months, complete cytogenetic
remission (CCyR) and major molecular response (MMR) were
achieved in 57% and 41% of patients, respectively. Patients
with high EUTOS risk scores achieved CCyR and MMR significantly
later than patients with low EUTOS risk. Probabilities of
overall survival (OS) and progression-free survival for all
patients at 12, 24 and 30 months was 97%, 94% and 92%, and 95%,
92% and 90%, respectively. The new EUTOS long-term survival
score was validated: the OS of patients differed significantly
between the three risk groups. The probability of dying in
remission was 1% after 24 months. The current management of
patients with tyrosine kinase inhibitors resulted in responses
and outcomes in the range reported from clinical trials. These
data from a large population-based, patient sample provide a
solid benchmark for the evaluation of new treatment policies.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI